Long Road For Daiichi Sankyo’s Quizartinib Gets Longer As FDA Extends Review Time

 
• By Alaric DeArment
  
The FDA extended the PDUFA date for Daiichi Sankyo's quizartinib by three months • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapeutic Category